Track record · closed signal

Novartis AG (NVS) — closed signal from February 27, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 28, 2026.

Predicted vs. what happened

NVS price · publication thesis → realized outcomesplit-adjusted
$169.48 Published $193.21 Target $151.40 Window close $170.46 Peak
$166.00 – $171.00Entry zone — fair-value band
$169.48Published — price the day we called it
$193.21Target — the price the thesis aimed for
$170.46Peak — highest point inside the window, not a realized return
$151.40Window close — end-of-window price, context only

What happened

Partial

Reached 4% of the predicted growth at its peak, without hitting the target.

Peak price
$170.46
peak on February 27, 2026 — not a realized return
Peak gain
+0.6%
peak, from the publication price
Window close
$151.40
end-of-window price, context only
Days to target
—
Window
February 27, 2026 – May 28, 2026

The thesis — published February 27, 2026

Predicted growth
+14%
over the measurement window
Target price
$193.21
the price the thesis aimed for
Entry zone
$166.00 – $171.00
the fair-value band we waited for
Price at publication
$169.48
published February 27, 2026
Confidence
78%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novartis could be a short-term trade because a recent regulatory positive opinion for remibrutinib gives the stock a near-term news boost. The price pulled back and might bounce if buyers step in to defend current levels. Main risk: the news attention fades or the wider healthcare market weakens, slowing any rebound.

Primary drivers

  • European regulatory nod for remibrutinib opens a path to market
  • Health-care stocks can draw safety-seeking buyers in choppy markets
  • Recent pullback creates a defined place to limit losses
  • U.S. radioligand factory builds a longer-term growth base

How it played out

NVS: the target was not reached

Lyra published NVS on 2026-02-27 at $169.48, with 14% expected growth toward $193.21. The thesis pointed to a European regulatory nod for remibrutinib, possible safety-seeking demand for health-care stocks, a recent pullback with a defined risk area, and a U.S. radioligand factory as a longer-term base.

Inside the window from 2026-02-27 to 2026-05-28, NVS peaked at $170.46 on 2026-02-27, up 0.6%. It never reached $193.21. The stock ended at $151.40. The published thesis missed on price action.

What happened during the window

On April 28, 2026, Novartis reported first-quarter 2026 results. IBD reported sales of $13.11 billion and core earnings of $1.99 per share. The article also said Novartis kept its 2026 outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVS signals